Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations: potential N-Nitrosodimethylamine (NDMA) amounts above levels established by the FDA.
| Brand name | NIZATIDINE |
| Generic name | NIZATIDINE |
| Active ingredient(s) | NIZATIDINE |
| Distributed by / for | Gemini Laboratories, LLC Bridgewater, NJ 08807 |
| NDC | 60846-301-15 |
| Full product label | Nizatidine Oral Solution, 15 mg/mL (75 mg/5mL) USP 480 mL bottles, Rx Only Distributed by: Gemini Laboratories, LLC Bridgewater, NJ 08807 NDC 60846-301-15 |
| Recalling firm | Amneal Pharmaceuticals of New York, LLC |
| Distribution | Nationwide |
| Quantity | 11258 bottles |
| Recall initiated | 2020-04-15 |
| Report date | 2020-05-06 |
| Recall completed | 2021-09-08 |
| Recall number | D-1253-2020 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Brookhaven NY United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗